14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$0.33 (-4.62%)

Volume: 39.314k

Closed: Sep 26, 2022

Hollow Logo Score: -6.268

Galmed Pharmaceuticals Ltd. Stock Forecast

$0.33 (-4.62%)

Volume: 39.314k

Closed: Sep 26, 2022

Score Hollow Logo -6.268

Galmed Pharmaceuticals Ltd. Company Profile

16 Tiomkin Street

Tel Aviv 6578317

972 3 693 8448

www.galmedpharma.com

Industry: Biotechnology

Sector: Healthcare

Galmed Pharmaceuticals Ltd.

Description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Hot Stocks To Watch:

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE